Study On Shenzhi Tongxin Capsule In The Treatment Of Silent Myocardial Ischemia With Qi Deficiency And Blood Stasis Syndrome

Objective: To observe the clinical efficacy of Shenzhi Tongxin capsules in the treatment of Cohn Ⅲ Slient Myocardial Ischemia syndrome of Qi deficiency and blood stasis,and predict the effect of Shenzhi Tongxin capsules in the treatment of slient myocardial ischemia(SMI)through network pharmacology mechanism.Methods: 1.Clinical observation research part: 60 SMI patients with Cohn Type Ⅲ were divided into two groups according to the random number table method.30 cases in the control group were treated with routine western medicine.30 cases in the treatment group were treated by Shenzhi Tongxin capsules on the basis of treatment in the control group.Both groups were observed for 4 weeks makes a period of treatment.Compare the TCM syndrome scores,the number of ST-segment depression in Holter(24h),the total duration of ST-segment depression,blood lipids[total triglycerides(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)],serum ischemic modified albumin(IMA),and high-sensitivity C-reactive protein(hs-CRP),serum lipoprotein-associated phospholipase A2(Lp-PLA2)before and after treatment between two groups.2.Network pharmacology research part: Apply the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP),BATMAN-TCM database,Gene Cards database,OMIM database,Pharm Gkb database,Dis Ge NET database to screen out the effective active ingredients of Shenzhi Tongxin Capsules in the treatment of SMI.Predict its role gene targets.Results: 1.Clinical observation and research results: TCM syndrome score,Holter(24h)ST-segment depression frequency and total ST-segment depression duration,TC,TG,LDL-C,IMA,hs-CRP,Lp-PLA2,treatment group Compared with the control group,both decreased,and the difference was statistically significant(P<0.05);in terms of HDL-C,both the treatment group and the control group increased,and the contrast difference was statistically significant(P<0.05).2.Network pharmacology research: In this study,a total of 120 main active ingredients of Shenzhi Tongxin Capsules were screened through the public database platform,totally 244 target gene of active components were obtained;GO enrichment analysis and KEGG pathway enrichment results respectively show that it is mainly related to the biological functions such as adrenergic receptor activity and the signal pathways such as MAPK,VEGF and PPAR.Conclusion: Shenzhi Tongxin Capsule combined with western medicine has a definite effect in the treatment of SMI with Cohn Type Ⅲ,which can alleviate the clinical symptoms of traditional Chinese medicine,reduce symptoms of TCM,reduce IMA,regulate blood lipids,and anti-inflammatory reactions.Shenzhi Tongxin Capsules can treat SMI through multiple targets such as APP,AKT1,MAPK1,ANXA1,adrenergic receptor activity,MAPK signaling pathway,VEGF signaling pathway,and PPAR signaling pathway.